Compare TG Therapeutics Inc (TGTX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Zillow Group Inc Class A — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Zillow Group Inc Class A trades at $31.83 (market cap $7.54B). The key difference: TG Therapeutics Inc and Zillow Group Inc Class A are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| TGTX | ZG | |
|---|---|---|
Market Cap | $8.26B | $7.54B |
Sector | Health | Media |
52-Week High | $59.06 | $86.76 |
52-Week Low | $26.39 | $29.14 |
Enterprise Value | $8.50B | $7.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Zillow Group (ZG) trades at $31.80, down 5.67% over 24 hours, amid a bearish technical signal and negative news flow. The company reported revenue of $2.58B in 2025 with a net income of $23M, marking a return to profitability after losses in prior years. However, a high P/E ratio of 131.36 suggests premium valuation, while recent earnings showed a mix of beats and misses. Multiple law firms have announced securities class action investigations related to an alleged anticompetitive agreement, contributing to investor uncertainty.
The outlook is clouded by legal risks and rich valuation, though analyst consensus remains positive with a $57.80 price target. Upside potential hinges on sustained revenue growth and margin expansion, but downside risks include litigation outcomes and competitive pressures. Investors should weigh the strong analyst buy rating against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
